乳腺癌患者术后辅助治疗的临床效果及其影响因素分析

doi:10.13481/j.1671-587x.20150338

Abstract

Abstract:

Objective To analyze the clinical pathologic characteristics, treatment and prognosis of 476 breast cancer patients, and to explore the related factors influencing the prognosis of breast cancer. Methods 476 breast cancer patients received postoperative adjuvant therapy were followed up who were diagnosed as the pathologic stage Ⅰ-Ⅲ from 2007 to 2010.The median follow-up time was 50.5 months.Kaplan-Meier method was used to draw the survival curve, and Log-rank test was used to compare the survival rates;COX proportional hazards model was used to analyze single factors and multiple factors.The risk factors related to the prognosis of breast cancer were analyzed. Results The 3-year disease free survival rate of the patients was 94.3%.The single factor analysis showed that age, tumor size, the number of metastatic lymph nodes, vascular tumor emboli, hormone receptor status, HER-2 expression and molecular subtypes were the influencing factors of disease free survival(DFS) (P<0.05).The smaller age, the larger neoplasm, the more metastatic lymph nodes, the more vascular tumor emboli, the lower positive rate of hormone receptor, the over-expression of HER-2, the molecular subtypes of HER-2 over-expression and the basal-like subtype had poor prognosis among them.The multifactor analysis demonstrated that hormone receptor status and HER-2 expression were independent factors influencing DFS (P<0.05).The 3-year overall rate of the patients was 97.6%.The single factor analysis showed that the tumor size, the number of metastatic lymph nodes, vascular tumor emboli, hormone receptor status and HER-2 expression were the influencing factors of overall survival (OS)(P<0.05).The multiple factor analysis demonstrated the number of metastatic lymph node, hormone receptor status and HER-2 expression were independent factors of OS (P<0.05). Conclusion The number of metastatic lymph nodes, hormone receptor status and HER-2 expression are significantly independent indicators of prognosis in the patients with breast cancer respectively.

Key words: breast neoplasms, adjuvant therapy, survival rate, prognostis

CLC Number:

R734.2

DONG Ying, KANG Lihua, GUAN Meng, LYU Zheng, SONG Yanqiu. Clinical effect and influencing factor analysis of postoperative adjuvant therapy for patients with breast cancer[J].Journal of Jilin University Medicine Edition, 2015, 41(03): 636-642.

References

[1] Zheng G, Peng F, Ding R, et al.Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis[J].Cancer Res Clin Oncol, 2010, 136(10):1477-1488.

[2] 中国抗癌协会.乳腺癌诊治指南与规范(2007 版) [J].中国癌症杂志, 2007, 17(5):412-413.

[3] 吴清然.中国女性乳腺癌危险因素的系统评价[J].现代预防医学, 2011, 38(1):61-72.

[4] 史建军, 刘涛, 李珂, 等.110例青年女性乳腺癌预后分析[J].中国妇幼保健, 2014, 29(9):1348-1350.

[5] Goldhirsch A, Glick JH, Gelber RD, et al.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005[J].Ann Oncol, 2005, 16(10):1569-1583.

[6] Goldhirsch A, Wood WC, Gelber RD, et al.Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J].Ann Oncol, 2007, 18(7): 1133-1144.

[7] Barni S, Venturini M, Molino A, et al.Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM) [J].Tumori, 2011, 97(5):559-563.

[8] Han W, Kang SY.Relationship between age at diagnosis and outcome of Premenopausal breast cancer:age less than 35 years is a reasonable cut off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1): 193-200.

[9] De la Rochefordiere A, Asselain B, Campana F, et al.Age as prognostic factor in premenopausal breast carcinoma[J].Lancet, 1993, 341(8852):1039-1043.

[10] Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313.

[11] Khanfir A, Frikha M, Kallel F, et al.Breast cancer in young women in the south of Tunisia[J].Cancer Radiother, 2006, 10(8):565-571.

[12] 黄波.COX比例风险模型分析乳腺癌的预后[J].当代医学, 2009, 15(10):76-77.

[13] Bonadonna G, Moliterni A, Zambetti M, et al.30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer:cohort study[J].BMJ, 2005, 330(7485):217-220.

[14] Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321.

[15] 秦颖, 张同先, 张巍, 等.青年乳腺癌临床病理特点分子分型及预后分析[J].中国肿瘤临床, 2014, 41(4):231-236.

[16] 张继运, 刘雨雄, 沙新海, 等.青年老年乳腺癌临床病理资料与预后的探讨[J].中华乳腺病杂志:电子版, 2012, 6(3):259-263.

[17] 周灿, 王珂, 何建军, 等.不同年龄段女性乳腺癌患者临床病理特征的回顾性分析[J].西安交通大学学报:医学版, 2013, 34(1):133-137.

[18] 王珂, 周灿, 谢四梅, 等.患者职业对乳腺癌临床病理特征及治疗模式的影响[J].西安交通大学学报:医学版, 2013, 34(2):218-223.

[19] 庄秀芬, 张幸平, 郭慧琳, 等.107 例乳腺癌患者综合治疗的疗效及预后分析[J].重庆医科大学学报, 2010, 35(1):130-134.

[20] 何建苗, 马小军, 赵华洲, 等.术前置泵区域动脉灌注化疗治疗晚期乳腺癌远期疗效分析[J].解放军医学杂志, 2014, 39(10):831-833.

[21] 武萍萍, 陶然, 彭攸, 等.EZH2及DNMT1在三阴性乳腺癌中的表达及意义[J].解放军医学杂志, 2015, 40(1):50-55.

[22] Berry D, Cirrineion C, Henderson I, et al.Estrogen-receptor status and outcome of modern chemotherapy for patients with node-positive breast cancer[J].JAMA, 2006, 295(14):1658-1667.

[23] Inic Z, Zegarac M, Inic M, et al.Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information[J].Clin Med Insights Oncol, 2014, 11(8):107-111.

[24] 陈崇, 周桃玉, 温旺荣.乳腺癌组织中 Ki-67表达及其临床意义的Meta分析[J].肿瘤学杂志, 2014(4):270-275.

[25] Gong P, Wang Y, Liu G, et al.New insight into Ki67 expression at the invasive front in breast cancer[J].PLoS One, 2013, 8(1):e54912.

Clinical effect and influencing factor analysis of postoperative adjuvant therapy for patients with breast cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	YU Xiuyan, ZHANG Xiaowei, CONG Zhanjie, LI Ting, WU Xuefeng. Detection of serum hMAM and CD147 levels of patients with breast cancer and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1269-1274.
[2]	ZHENG Fang, OUYANG Zhengren, OUYANG Jinglin, ZHOU Shili, LUO Wen. Analysis on correlations between ultrasound features and positive expressions of CerbB-2and Ki-67 in patients with breast cancer [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1073-1077.
[3]	LI Xiao, QIU Xiang, MA Zhenhui, TIAN Yaping. Skin metastatic carcinoma complicated with herpes zoster:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 825-827.
[4]	MA Hongyun, ZHUANG Xinming, XU Weiguo, LIU Yi. Inhibitory effects of hyaluronic acid nanoparticles loading doxorubicin and cisplatin on allograft breast cancer in mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 243-248.
[5]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[6]	QI Yali, LIU Yang, LIANG Shuo, GONG Shouliang, WANG Zhicheng, LIU Weiwu. Effects of Smac overexpression mediated by triple-targeting on apoptosis and cell cycle progression of breast cancer MDA-MB-231 cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 90-94.
[7]	MA Xiaotian, YUE Xiaoxin, RONG Shouhua, ZHANG Yuchao, TIAN Yuan, SHI Ying, LI Junfang, JIA Liting. Inhibitory effect of miR-200c on epithelial-mesenchymal transiton in triple negative breast cancer and its mechanism [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 106-110.
[8]	GAO Xinya, ZHANG Weijie, CUI Li, ZHOU Xueliang, MA Zhijun, LYU Zhuan, CHI Yanyan, WANG Liuxing. Expression of TM4SF1 in breast cancer tissue and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1186-1192.
[9]	NIU Huikun, QU Yangming, LI Meiqi, LI Lu, LYU Xin, SONG Yuanyuan, GAO Chunshi, LI Bo. Meta-analysis on efficacy and adverse effects of neoadjuvant chemotherapy combined with capecitabine in treatment of breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1171-1176.
[10]	YU Xiuyan, ZHANG Xiaowei, YE Lili, LI Ting, LIU Xiaofeng, WU Xuefeng. Application of detection of expressions of hMAM combined with MMP-9 and C-erbB2 mRNA in peripheral blood in diagnosis of micrometastases of breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1009-1014.
[11]	ZHAO Peng, FU Tong, ZHANG Xiuxiang, ZHAN Yue, GUAN Xin, SHI Aiping. A case report of breast cancer complicated with thyroid cancer and dermatomyositis and literature review about relationships between three kinds of diseases [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1015-1018.
[12]	REN Aihua, WANG Dawei. Influence ofHiwigene targeting silencein chemotherapy sensitivity of breast cancerMCF-7/ADMcells [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 743-746.
[13]	WANG Jianan, FENG Hui, WANG Qian, HE Yueming, SONG Yanqiu, ZHU Jihong. Killer effect of natural killer cells combined with tamoxifen on breast cancer cells in vitro and its mechanism [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 281-287.
[14]	ZHENG Wen, CHEN Baofeng, LI Jie, ZHOU Yingying. Application value of high frequence ultrasound in reinjection of facial autologous fat granule injection transplantation [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 170-175.
[15]	MA Chunhu, CHENGLuyang, LIU Lei, XU Yana, Zhao Enhong, LIU Chengyi, WANG Lixin, XIA Aihua, JING Xinyao, LIU Xinghua. Significance of detection of multiple marker genes in cancer cells in peripheral blood in predication of metastases and prognosis of breast cancer patients [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 85-90.